Skip to main content

Table 1 Primers used in the study

From: Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer

Genes

Sequences (5′-3′)

BCL-2

F: TGTGTGTGGAGAGCGTCAAC

R: GACAGCCAGGAGAAATCAAAC

GAPDH

F: AGCCACATCGCTCAGACAC

R: GCCCAATACGACCAAATCC

IL6

F: TACCCCCAGGAGAAGATTCC

R: TTTTCTGCCAGTGCCTCTTT

IL-8

F: CTGGACCCCAAGGAAAACTG

R: TTCTCAGCCCTCTTCAAAAAC

SVV

F: GAACTGGCCCTTCTTGGAG

R: AAGTCTGGCTCGTTCTCAGTG

TGFβ1

F: TGCTAATGGTGGAAACCCACAACG

R: TCTCGGAGCTCTGATGTGTTGAAG

TNFA

F: CTCCTCACCCACACCATCAG

R: GGAAGACCCCTCCCAGATAG

VEGF

F: GTGATGATTCTGCCCTCCTC

R: CCTTGCTGCTCTACCTCCAC

  1. BCL-2 B-cell lymphoma 2, GAPDH glyceraldehyde 3-phosphate dehydrogenase, IL6 interleukin 6, IL8 interleukin 8, SVV survivin, TGFβ1 transforming growth factor β1, TNFA tumor necrosis factor α, VEGF vascular endothelial growth factor